Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)

  • Technology appraisal
  • TA351
  • Published: 

History

Documents created during the development process.

Coronary heart disease - cangrelor: draft scope for consultation (pre-referral) - November 2013

Coronary heart disease - cangrelor: provisional matrix (pre-referral) - November 2013